ArticleTherapeutic advances in hematology2012
The role of intravenous iron in the treatment of anemia in cancer patients.
Article in Therapeutic advances in hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea.PLoS medicine · 2020Trial
- A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.Pharmacotherapy · 2016Trial
- Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2022Review
- Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2020Review
- Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.Redox biology · 2018Article
- Iron in the Tumor Microenvironment-Connecting the Dots.Frontiers in oncology · 2018Review
- Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Safety of intravenous iron use in chronic kidney disease.Current opinion in nephrology and hypertension · 2016Review
- Article
- Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.International journal of nephrology and renovascular disease · 2016Review
- Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?International journal of molecular sciences · 2015Review
- Article
- Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.American journal of clinical pathology · 2014Article
- Anemia in inflammatory bowel disease: an under-estimated problem?Frontiers in medicine · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a major cause of morbidity in cancer patients resulting in poor physical performance, prognosis and therapy outcome. Initially, erythropoietin-stimulating agents (ESAs) were supposed to be the treatment of choice but about one third of patients turned out to be nonresponders and meta-analyses provided evidence of an increased risk of mortality if used excessively. This along with the successful use of intravenous iron for anemia in patients with chronic kidney disease prompted seven clinical studies evaluating the efficacy of intravenous iron as an adjunct to ESAs and four additional studies using intravenous iron only for anemia in cancer patients. These studies confirmed a superior response if ESAs are combined with intravenous iron and revealed iron only to be a useful option in patients with mild and absolute iron deficiency (AID). Currently, best treatment decisions for anemia in cancer might be based on measurements of serum ferritin (SF), transferrin saturation (TSAT), soluble transferrin receptor (sTfR), ferritin index (FI = sTfR/log SF), hypochromic reticulocytes (CHR) and C-reactive protein (CRP). However, there is still an urgent need for trials investigating diagnostic approaches to optimize therapy of anemia in cancer patients with iron and/or ESAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.